Skip to main content

Advertisement

SpringerLink
Log in

Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus

  • Original Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Purpose

Osteopontin (OPN), osteoprotegerin (OPG) and osteocalcin (OC) are matrix glycoproteins which mediate bone mineralization; moreover, their effects on glucose/insulin homeostasis have recently been demonstrated. Higher circulating OPN and OPG levels have been associated with the presence of insulin resistance, atherosclerosis and coronary heart disease. No data are available on contextual changes of these markers in type 2 diabetes mellitus (T2DM). Therefore, aims of this study were to evaluate serum OPN, OPG and OC levels in T2DM patients and their clinical correlates.

Methods

We recruited 83 consecutive T2DM patients referring to our diabetes outpatient clinics at Sapienza, University of Rome, and 71 non-diabetic sex and age-comparable subjects as a control group. Study population underwent metabolic characterization and carotid ultrasound for intima–media thickness measurement. Plasma OPN, OPG and OC were measured by MILLIPLEX Multiplex Assays Luminex.

Results

T2DM patients had significantly higher circulating OPN and OPG levels than controls (14.3 ± 13.6 vs 10.6 ± 13.7 ng/ml p < 0.001, 0.70 ± 0.60 vs 0.54 ± 4.1 ng/ml, p = 0.02) while OC levels were similar in the two cohorts (6.35 ± 5.8 vs 7.80 ± 7.0 ng/ml, p = n.s). OPN and OPG positively correlated with greater systolic blood pressure (SBP) values, HOMA-IR and HOMA-β, and with the presence of dyslipidemia and carotid atherosclerosis. The association between greater OPN and OPG levels and SBP was independent from possible confounders (both p = 0.01).

Conclusions

Circulating OPN and OPG levels are increased in T2DM patients and identify a particularly unfavourable metabolic profile, mostly expressed by higher SBP. Bone peptides may represent novel markers of vascular stress and accelerated atherosclerosis in diabetes, constituting a possible tool for cardiovascular risk stratification in diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Chapman J, Miles PD, Ofrecio JM, Neels JG, Yu JG, Resnik JL, Wilkes J, Talukdar S, Thapar D, Johnson K, Sears DD (2010) Osteopontin is required for the early onset of high fat diet-induced insulin resistance in mice. PLoS One 5:e13959. https://doi.org/10.1371/journal.pone.0013959

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Kiefer FW, Neschen S, Pfau B, Legerer B, Neuhofer A, Kahle M, Hrabé de Angelis M, Schlederer M, Mair M, Kenner L, Plutzky J, Zeyda M, Stulnig TM (2011) Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice. Diabetologia 54:2132–2142. https://doi.org/10.1007/s00125-011-2170-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Morisawa T, Nakagomi A, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W (2015) Osteoprotegerin is associated with endothelial function and predicts early carotid atherosclerosis in patients with coronary artery disease. Int Heart J 56:605–612. https://doi.org/10.1536/ihj.15-150

    Article  CAS  PubMed  Google Scholar 

  4. García-Martín A, Rozas-Moreno P, Reyes-García R, Morales-Santana S, García-Fontana B, García-Salcedo JA et al (2012) Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 97(1):234–241

    Article  CAS  PubMed  Google Scholar 

  5. Morales-Santana S, García-Fontana B, García-Martín A, Rozas-Moreno P, García-Salcedo JA, Reyes-García R et al (2013) Atherosclerotic disease in type 2 diabetes is associated with an increase in sclerostin levels. Diabetes Care 36(6):1667–1674

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Novo-Rodríguez C, García-Fontana B, Luna-Del Castillo JD, Andújar-Vera F, Ávila-Rubio V, García-Fontana C et al (2018) Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS One 13(6):e0199504

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Rubin MR, Silverberg SJ (2004) Vascular calcification and osteoporosis—the nature of the nexus. J Clin Endocrinol Metab 89:4243–4245

    Article  CAS  PubMed  Google Scholar 

  8. Singh DK, Winocour P, Summerhayes B, Kaniyur S, Viljoen A, Sivakumar G, Farrington K (2012) Prevalence and progression of peripheral vascular calcification in type 2 diabetes subjects with preserved kidney function. Diabetes Res Clin Pract 97:158–165. https://doi.org/10.1016/j.diabres.2012.01.038

    Article  CAS  PubMed  Google Scholar 

  9. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM (2009) RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res 104:1041–1048. https://doi.org/10.1161/CIRCRESAHA.108.189001

    Article  CAS  PubMed  Google Scholar 

  10. Pollack RM, Donath MY, LeRoith D, Leibowitz G (2016) Anti-inflammatory agents in the treatment of diabetes and its vascular complications. Diabetes Care 39:S244–252. https://doi.org/10.2337/dcS15-3015

    Article  CAS  PubMed  Google Scholar 

  11. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM (1994) Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 74:214–224

    Article  CAS  PubMed  Google Scholar 

  12. Lewis JR, Lim WH, Ueland T, Wong G, Zhu K, Lim EM, Bollerslev J, Prince RL (2015) Elevated circulating osteoprotegerin and renal dysfunction predict 15-year cardiovascular and all-cause mortality: a prospective study of elderly women. PLoS One 7:e0134266. https://doi.org/10.1371/journal.pone.0134266

    Article  CAS  Google Scholar 

  13. Callegari A, Coons ML, Ricks JL, Rosenfeld ME, Scatena M (2014) Increased calcification in osteoprotegerin-deficient smooth muscle cells: dependence on receptor activator of NF-κB ligand and interleukin 6. J Vasc Res 51:118–131. https://doi.org/10.1159/000358920

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL (2008) Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(−/−) mice. Circulation 117:411–420

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Zoch ML, Clemens TL, Riddle RC (2016) New insights into the biology of osteocalcin. Bone 82:42–49. https://doi.org/10.1016/j.bone.2015.05.046

    Article  CAS  PubMed  Google Scholar 

  16. Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M et al (2003) Global diabetic retinopathy project group. Proposed international clinical retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682

    Article  CAS  Google Scholar 

  17. Matsuda M, DeFronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22:1462–1470

    Article  CAS  PubMed  Google Scholar 

  18. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31–41

    Article  CAS  PubMed  Google Scholar 

  19. Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z et al (2018) The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetol 55(2):139–148

    Article  CAS  PubMed  Google Scholar 

  20. Berezin AE, Kremzer AA (2013) Circulating osteopontin as a marker of early coronary vascular calcification in type two diabetes mellitus patients with known asymptomatic coronary artery disease. Atherosclerosis 229:475–481. https://doi.org/10.1016/j.atherosclerosis.2013.06.003

    Article  CAS  PubMed  Google Scholar 

  21. Yan X, Sano M, Lu L, Wang W, Zhang Q, Zhang R, Wang L, Chen Q, Fukuda K, Shen W (2010) Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 9:70. https://doi.org/10.1186/1475-2840-9-70

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Barchetta I, Alessandri C, Bertoccini L, Cimini FA, Taverniti L, Di Franco M, Fraioli A, Baroni MG, Cavallo MG (2016) Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile. Eur J Endocrinol 174:187–192. https://doi.org/10.1530/EJE-15-0791

    Article  CAS  PubMed  Google Scholar 

  23. Zwakenberg SR, van der Schouw YT, Schalkwijk CG, Spijkerman AMW, Beulens JWJ (2018) Bone markers and cardiovascular risk in type 2 diabetes patients. Cardiovasc Diabetol 17(1):45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM (2003) Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol 149:39–42

    Article  CAS  PubMed  Google Scholar 

  25. Duan P, Yang M, Wei M, Liu J, Tu P (2017) Serum osteoprotegerin is a potential biomarker of insulin resistance in Chinese postmenopausal women with prediabetes and type 2 diabetes. Int J Endocrinol 2017:8724869. https://doi.org/10.1155/2017/8724869

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sanchez-Enriquez S, Ballesteros-Gonzalez IT, Villafán-Bernal JR, Pascoe-Gonzalez S, Rivera-Leon EA, Bastidas-Ramirez BE, Rivas-Carrillo JD, Alcala-Zermeno JL, Armendariz-Borunda J, Llamas-Covarrubias IM, Zepeda-Moreno A (2017) Serum levels of undercarboxylated osteocalcin are related to cardiovascular risk factors in patients with type 2 diabetes mellitus and healthy subjects. World J Diabetes 8:11–17. https://doi.org/10.4239/wjd.v8.i1.11

    Article  PubMed  PubMed Central  Google Scholar 

  27. Vigili de Kreutzenberg S, Fadini GP, Guzzinati S, Mazzucato M, Volpi A, Coracina A, Avogaro A (2015) Carotid plaque calcification predicts future cardiovascular events in type 2 diabetes. Diabetes Care 38:1937–1944. https://doi.org/10.2337/dc15-0327

    Article  CAS  PubMed  Google Scholar 

  28. Bessueille L, Fakhry M, Hamade E, Badran B, Magne D (2015) Glucose stimulates chondrocyte differentiation of vascular smooth muscle cells and calcification: a possible role for IL-1β. FEBS Lett 589:2797–2804. https://doi.org/10.1016/j.febslet.2015.07.045

    Article  CAS  PubMed  Google Scholar 

  29. Rozas Moreno P, Reyes García R, García-Martín A, Varsavsky M, García-Salcedo JA, Muñoz-Torres M (2013) Serum osteoprotegerin: bone or cardiovascular marker in type 2 diabetes males? J Endocrinol Invest 36:16–20. https://doi.org/10.3275/8285

    Article  CAS  PubMed  Google Scholar 

  30. Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE (2014) Relationships between osteoprotegerin, receptor activator of the nuclear factor kB ligand and serum levels and carotid intima-media thickness in patients with type 2 diabetes mellitus. Panminerva Med 56:221–225

    CAS  PubMed  Google Scholar 

  31. Jung CH, Lee WY, Kim SY, Jung JH, Rhee EJ, Park CY, Mok JO, Oh KW, Kim CH, Park SW, Kim SW (2010) The relationship between coronary artery calcification score, plasma osteoprotegerin level and arterial stiffness in asymptomatic type 2 DM. Acta Diabetol 47:145–152. https://doi.org/10.1007/s00592-009-0154-z

    Article  CAS  PubMed  Google Scholar 

  32. Poulsen MK, Nybo M, Dahl J, Hosbond S, Poulsen TS, Johansen A, Høilund-Carlsen PF, Beck-Nielsen H, Rasmussen LM, Henriksen JE (2011) Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. Cardiovasc Diabetol 10:76. https://doi.org/10.1186/1475-2840-10-76

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R (2006) The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol 47:1850–1857

    Article  CAS  PubMed  Google Scholar 

  34. Anand DV, Lim E, Darko D, Bassett P, Hopkins D, Lipkin D, Corder R, Lahiri A (2007) Determinants of progression of coronary artery calcification in type 2 diabetes role of glycemic control and inflammatory/vascular calcification markers. J Am Coll Cardiol 50:2218–2225

    Article  CAS  PubMed  Google Scholar 

  35. Leslie WD, Rubin MR, Schwartz AV, Kanis JA (2007) Type 2 diabetes and bone. J Bone Miner Res 27:223–2237

    Google Scholar 

Download references

Funding

This work was funded by research grants from the Sapienza Ateneo Scientific Research.

Author information

Author notes

  1. I. Barchetta and V. Ceccarelli contributed equally to this work.

Authors and Affiliations

  1. Department of Experimental Medicine, Section of Medical Pathophysiology, Food Science and Endocrinology, Sapienza University of Rome, Rome, Italy

    I. Barchetta, V. Ceccarelli, F. A. Cimini, L. Bertoccini, A. Lenzi, M. G. Baroni & M. G. Cavallo

  2. Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy

    A. Fraioli & C. Alessandri

Authors
  1. I. Barchetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Ceccarelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. A. Cimini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. Bertoccini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Fraioli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Alessandri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Lenzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. G. Baroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. G. Cavallo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. G. Cavallo.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Consent for publication

All authors of the manuscript have read and agreed to its content and are accountable for all aspects of the accuracy and integrity of the manuscript. Submitted article is original, it has not already been published in other journal, and is not currently under consideration by another journal.

Availability of data and materials

The data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barchetta, I., Ceccarelli, V., Cimini, F.A. et al. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus. J Endocrinol Invest 42, 513–520 (2019). https://doi.org/10.1007/s40618-018-0941-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-018-0941-x

Keywords

Search

Navigation